SL
AMPH icon

Salomon & Ludwin’s Amphastar Pharmaceuticals AMPH Stock Holding History

Salomon & Ludwin’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-229
Closed -$6.12K – 2101
2025
Q4 		$6.12K Sell
229
-148
-39% -$3.81K ﹤0.01% 1707
2025
Q3 		$10.1K Buy
+377
New +$9.73K ﹤0.01% 1299

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Salomon & Ludwin's AMPH Position: Q1 2026 in Review

Salomon & Ludwin sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 229 shares — an estimated $6.12K sold.

Salomon & Ludwin first reported a position in AMPH in Q3 2025 and held it in 2 quarters. The position peaked at $10.1K in Q3 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Salomon & Ludwin reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Salomon & Ludwin sold 229 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $6.12K.
  • Salomon & Ludwin first reported a position in Amphastar Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Salomon & Ludwin's Amphastar Pharmaceuticals position peaked at $10.1K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.